A Phase 3 interventional study of Azacitidine and Physician Choice in Myelodysplastic Syndromes, sponsored by Celgene. Completed at 108 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-29.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 130 studies testing azacitidine in Myelodysplastic Syndromes — 13 open to participants now, 25 under way, 3 of them phase 3. Azacitidine · Myelodysplastic Syndromes.
Among the 130 studies testing azacitidine in Myelodysplastic Syndromes, this one is the 3rd largest by enrollment of the 126 interventional ones that give a count, is the only one that started in 2003, is one of 9 in phase 3, and was the 4th registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.
Browse Myelodysplastic Syndromes studies →13 of the 130 studies testing azacitidine in Myelodysplastic Syndromes are open now, in 12 countries. Recruiting first, the newest first:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70
City of Hope Medical Center · Sites in United States
Ages 18–75
Medical College of Wisconsin · Sites in United States
Ages 18+
Institut de Recherches Internationales Servier · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Beijing 302 Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
130 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 50 · Phase 2 86 · Phase 3 12 · Phase 4 3
First in 2000; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 358 is above the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 38 across the 126 interventional studies. Of the 88 that completed or were terminated, 42 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 130 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb: 4 open now, 9 under way, 5 of them phase 3. Of 63 finished, 20 (32%) have results posted.
Among the 75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb, this one is the 4th largest by enrollment of the 46 interventional ones that give a count, is one of 3 that started in 2003, is one of 11 in phase 3, and was the 6th registered.
Bristol-Myers Squibb’s Myelodysplastic Syndromes studies by the year they started, since 2001.
9 of the studies testing azacitidine in Myelodysplastic Syndromes that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06465953Phase 3Institut de Recherches Internationales ServierIvosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation | 2027-11-01 |
| NCT05788679Karolinska University HospitalA Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS | 2026-12 |
| NCT00392353National Cancer Institute (NCI)Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | 2026-12-31 |
| NCT06502145Medical College of WisconsinIadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome | 2026-12-31 |
| NCT03862157M.D. Anderson Cancer CenterAzacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | 2027-01-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 130 studies testing azacitidine in Myelodysplastic Syndromes, from their registry updates:
Among Bristol-Myers Squibb’s 75 in Myelodysplastic Syndromes:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether patients with high-risk myelodysplastic syndromes (MDS) treated with azacitidine have improved survival compared to conventional care treatments. The study will also assess the effect of treatments on response, duration of response, and transformation to acute myeloid leukemia (AML). The study will continue for 12 months following last patient enrolled.
See study AZA PH GL 2003 CL 001 E for information about the extension to this study.
Comparison/Control Interventions offered the physician three options:
All three options included best supportive care. Neither the experimental group (azacitidine) nor any of the comparison/control options allowed use of erythropoietin.
Duration of Intervention: Patients will be treated until death, withdrawal, unacceptable toxicity or conclusion of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study Drug plus best supportive care. Treatment with erythropoietin was not permitted
Drug: Azacitidine
Physician choice of low dose cytarabine (plus best supportive care), standard chemotherapy (plus best supportive care) or best supportive care (only). Treatment with erythropoietin was not permitted
Other: Physician Choice
Azacitidine was injected subcutaneously (SC) at an initial dose of 75mg/m\^2/day for 7 days. The 7-day dosing was repeated every 28 days with dose adjustment based on predefined hematology and renal laboratory results. Number of cycles: Azacitidine treatment was to be continued until the end of the study unless treatment was discontinued due to unacceptable toxicity, relapse after complete or partial response, transformation to AML or disease progression.
Also known as: AZA
Physician Choice was one of three options: * Best supportive care (BSC) alone, * Low-dose cytarabine subcutaneously for 14 days every 28 to 42 days, or * Standard chemotherapy administered for induction as a continuous intravenous infusion of cytarabine over 7 days plus an anthracycline (daunorubicin, idarubicin, or mitoxantrone) on Days 1, 2, and 3; and, for those eligible, 1 or 2 consolidation cycles administered as continuous intravenous infusions of cytarabine for 3 to 7 days with the same anthracycline that was used at induction on Days 1 and 2 (each cycle between 28 to 70 days from the start of the previous cycle). All three options included best supportive care
Also known as: cytarabine, anthracycline
Kaplan-Meier Estimates for Median Time to Death From Any Cause
Kaplan-Meier estimates for the median months until death from any cause within the intent-to-treat population. Patients surviving at the end of the follow-up period were censored at the date of last contact. If a patient withdrew consent to follow-up or was lost to follow-up, the patient was censored as of the last date of contact.
Time frame: Day 1 (randomization) to 42 months
Summary of Subgroup Analyses for Kaplan-Meier Estimates for Time to Death From Any Cause
Kaplan-Meier estimates for the median months until death from any cause within the intent-to-treat population. Patients surviving at the end of the follow-up period were censored at the date of last contact. If a patient withdrew consent to follow-up or was lost to follow-up, the patient was censored as of the last date of contact. Subgroups that were analyzed are age, gender, French-American-British (FAB) classification, World Health Organization (WHO) classification and International Prognostic Scoring System (IPSS) classification.
Time frame: Day 1 (randomization) to 42 months
Number of Participants Who Died
Count of participants who died during the study
Time frame: 42 months
Kaplan-Meier Estimate for Median Time to Transformation to Acute Myeloid Leukemia (AML) or Death From Any Cause, Whichever Occurred First
The time to transformation to AML or death from any cause (whichever occurred first) was defined as the number of days from the date of randomization until the date of documented AML transformation or death from any cause. Patients who did not transform to AML or die were censored at the date of last follow-up.
Time frame: Day 1 (randomization) to 42 months
Kaplan-Meier Estimates for Median Time to Transformation to Acute Myeloid Leukemia (AML)
The time to transformation to AML was defined as the number of days from the date of randomization until the date of documented AML transformation, defined as a bone marrow blast count ≥ 30% independent of baseline bone marrow count. Patients who did not transform to AML were censored at the date of last follow-up or date of death.
Time frame: Day 1 (randomization) to 42 months
Summary of Participants' Red Blood Cell (RBC) Transfusion Status for Participants Who Were Transfusion Dependent at Baseline
Summary of dependence and independence from red blood cell (RBC) transfusion at baseline and during treatment, for patients who were dependent at baseline. A patient was considered transfusion independent at baseline if the patient had no transfusions during the 56 days prior to randomization. During study, a patient was considered transfusion independent during the on-treatment period if the patient had no transfusions during any 56 consecutive days or more. Otherwise, the patient was considered transfusion dependent.
Time frame: Day 1 (randomization) to 42 months
Summary of Participants' Red Blood Cell (RBC) Transfusion Status for Participants Who Were Transfusion Independent at Baseline
Summary of dependence and independence from red blood cell (RBC) transfusion at baseline and during treatment, for patients who were independent at baseline. A patient was considered transfusion independent at baseline if the patient had no transfusions during the 56 days prior to randomization. During study, a patient was considered transfusion independent during the on-treatment period if the patient had no transfusions during any 56 consecutive days or more. Otherwise, the patient was considered transfusion dependent.
Time frame: Day 1 (randomization) to 42 months
Summary of Participants' Platelet Transfusion Status for Participants Who Were Transfusion Dependent at Baseline
Summary of dependence and independence from platelet transfusion at baseline and during treatment for patients who were dependent at baseline. A patient was considered transfusion independent at baseline if the patient had no transfusions during the 56 days prior to randomization. During study, a patient was considered transfusion independent during the on-treatment period if the patient had no transfusions during any 56 consecutive days or more. Otherwise, the patient was considered transfusion dependent.
Time frame: Day 1 (randomization) to 42 months
Summary of Participants' Platelet Transfusion Status for Participants Who Were Transfusion Independent at Baseline
Summary of dependence and independence from platelet transfusion at baseline and during treatment for patients who were independent at baseline. A patient was considered transfusion independent at baseline if the patient had no transfusions during the 56 days prior to randomization. During study, a patient was considered transfusion independent during the on-treatment period if the patient had no transfusions during any 56 consecutive days or more. Otherwise, the patient was considered transfusion dependent.
Time frame: Day 1 (randomization) to 42 months
Number of Participants Considered Hematologic Responders by Investigator Determinations Using International Working Group (IWG 2000) Criteria for Myelodysplastic Syndrome (MDS)
Investigator determined responses followed IWG criteria for * complete remission(CR): repeat bone marrow show \<5% myeloblasts, and peripheral blood evaluations lasting \>=2 months of hemoglobin(\>110 g/L), neutrophils(\>=1.5x10\^9/L), platelets(\>=100x10\^9/L), blasts (0%) and no dysplasia * partial remission(PR) is the same as CR for peripheral blood: bone marrow shows blasts decrease by \>=50% or a less advanced FAB classification from pretreatment * stable disease(SD) is a failure to achieve at least a partial remission, but with no evidence of progression for at least 2 months.
Time frame: Day 1 to 42 months
Number of Participants Showing Hematologic Improvement Using International Working Group (IWG 2000) Criteria for Myelodysplastic Syndrome (MDS) Assessed by Independent Review Committee
IWG 2000 Criteria: Pretreatment=hemoglobin \<100g/L or RBC transfusion-dependent, platelet count \<100x10\^9/L or platelet transfusion dependent, absolute neutrophil count \<1.5x10\^9/L. Erythroid response: Major-\>20g/L increase or transfusion independent. Minor- 10-20g/L increase or \>=50% decrease in transfusion requirements. Platelet response: Major-absolute increase of \>=30x10\^9/L or platelet transfusion independence. Minor-\>=50% increase. Neutrophil response: Major-\>=100% increase or an absolute increase of \>0.5x10\^9/L. Minor-\>=100% increase and absolute increase of \<0.5x10\^9/L.
Time frame: Day 1 to 42 months
Time to Disease Progression, Relapse After Complete or Partial Remission, or Death From Any Cause
The time to disease progression, relapse after complete or partial remission (CR, PR), or death from any cause was defined as the time from the date of randomization until the first date of documented disease progression, relapse after CR or PR, or death from any cause.
Time frame: Day 1 (randomization) to 42 months
Duration of Any Hematologic Improvement
The duration of improvement was defined as the time from the date of hematologic improvement until the date of first documented progression or relapse after hematologic improvement or death from any cause.
Time frame: Day 1 (randomization) to 42 months
Number of Infections Per Treatment Year Requiring Intravenous Antibiotics, Antifungals or Antivirals
The on-treatment adverse event rate of infection requiring IV antibiotics, antifungals, or antivirals per patient-years. The on-treatment period was considered the period from the date of randomization to the last treatment study visit.
Time frame: Day 1 (randomization) to 42 months
Number of Participants in Different Categories of Adverse Experiences During Core Study Period
Patient counts for a variety of subsets of adverse experiences for the core study period (day 1 to 42 months). The individual options for Conventional Care Regimens (Best Supportive Care Only, Low-Dose Cytarabine, and Standard Chemotherapy) are presented as separate treatments.
Time frame: Day 1 (randomization) to 42 months
| Milestone | Azacitidine | Conventional Care |
|---|---|---|
| Started | 179 | 179 |
| Completed | 109 | 81 |
| Not completed | 70 | 98 |
| Withdrew: Adverse event | 19 | 10 |
| Withdrew: Protocol violation | 1 | 7 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Withdrawal by subject | 15 | 37 |
| Withdrew: Physician decision | 0 | 2 |
| Withdrew: Lack of efficacy | 11 | 18 |
| Withdrew: Disease progression | 23 | 20 |
| Withdrew: Different central+local pathology review | 0 | 1 |
| Withdrew: Not documented | 0 | 2 |
Kaplan-Meier estimates for the median months until death from any cause within the intent-to-treat population. Patients surviving at the end of the follow-up period were censored at the date of last contact. If a patient withdrew consent to follow-up or was lost to follow-up, the patient was censored as of the last date of contact.
| months | Azacitidine | Conventional Care |
|---|---|---|
| Kaplan-Meier Estimates for Median Time to Death From Any Cause | 24.46 | 15.02 |
Kaplan-Meier estimates for the median months until death from any cause within the intent-to-treat population. Patients surviving at the end of the follow-up period were censored at the date of last contact. If a patient withdrew consent to follow-up or was lost to follow-up, the patient was censored as of the last date of contact. Subgroups that were analyzed are age, gender, French-American-British (FAB) classification, World Health Organization (WHO) classification and International Prognostic Scoring System (IPSS) classification.
| months | Azacitidine | Conventional Care |
|---|---|---|
| Age <65 years | 11.31 | 7.87 |
| Age >= 65 years | 24.46 | 13.87 |
| Age >= 75 years | 8.92 | 6.20 |
| Gender: Male | 24.46 | 15.02 |
| Gender: Female | 25.11 | 14.85 |
| FAB: Refractory anemia with excess blasts (RAEB) | 34.66 | 15.21 |
| FAB: RAEB in transformation | 17.25 | 15.25 |
| WHO: RAEB 1 | 11.54 | 6.72 |
| WHO: RAEB 2 | 21.11 | 15.02 |
| WHO: Other (AML, CMMoL-1 and 2, indeterminate) | 20.46 | 15.25 |
| IPSS: Intermediate 2 | 34.66 | 16.89 |
| IPSS: High | 19.21 | 14.52 |
The time to transformation to AML or death from any cause (whichever occurred first) was defined as the number of days from the date of randomization until the date of documented AML transformation or death from any cause. Patients who did not transform to AML or die were censored at the date of last follow-up.
| months | Azacitidine | Conventional Care |
|---|---|---|
| Kaplan-Meier Estimate for Median Time to Transformation to Acute Myeloid Leukemia (AML) or Death From Any Cause, Whichever Occurred First | 13.02 (9.9 to 15.0) | 7.61 (5.4 to 9.8) |
The time to transformation to AML was defined as the number of days from the date of randomization until the date of documented AML transformation, defined as a bone marrow blast count ≥ 30% independent of baseline bone marrow count. Patients who did not transform to AML were censored at the date of last follow-up or date of death.
| months | Azacitidine | Conventional Care |
|---|---|---|
| Kaplan-Meier Estimates for Median Time to Transformation to Acute Myeloid Leukemia (AML) | 20.66 (14.9 to 25.5) | 15.44 (12.4 to 22.5) |
Summary of dependence and independence from red blood cell (RBC) transfusion at baseline and during treatment, for patients who were dependent at baseline. A patient was considered transfusion independent at baseline if the patient had no transfusions during the 56 days prior to randomization. During study, a patient was considered transfusion independent during the on-treatment period if the patient had no transfusions during any 56 consecutive days or more. Otherwise, the patient was considered transfusion dependent.
| participants | Azacitidine | Conventional Care |
|---|---|---|
| Baseline Dependent; On-Treatment Independent | 50 | 13 |
| Baseline Dependent; On-Treatment Dependent | 61 | 101 |
Summary of dependence and independence from red blood cell (RBC) transfusion at baseline and during treatment, for patients who were independent at baseline. A patient was considered transfusion independent at baseline if the patient had no transfusions during the 56 days prior to randomization. During study, a patient was considered transfusion independent during the on-treatment period if the patient had no transfusions during any 56 consecutive days or more. Otherwise, the patient was considered transfusion dependent.
| participants | Azacitidine | Conventional Care |
|---|---|---|
| Baseline Independent; On-Treatment Independent | 58 | 37 |
| Baseline Independent; On-Treatment Dependent | 10 | 28 |
Summary of dependence and independence from platelet transfusion at baseline and during treatment for patients who were dependent at baseline. A patient was considered transfusion independent at baseline if the patient had no transfusions during the 56 days prior to randomization. During study, a patient was considered transfusion independent during the on-treatment period if the patient had no transfusions during any 56 consecutive days or more. Otherwise, the patient was considered transfusion dependent.
| participants | Azacitidine | Conventional Care |
|---|---|---|
| Baseline Dependent; On-Treatment Independent | 16 | 11 |
| Baseline Dependent; On-Treatment Dependent | 22 | 16 |
Summary of dependence and independence from platelet transfusion at baseline and during treatment for patients who were independent at baseline. A patient was considered transfusion independent at baseline if the patient had no transfusions during the 56 days prior to randomization. During study, a patient was considered transfusion independent during the on-treatment period if the patient had no transfusions during any 56 consecutive days or more. Otherwise, the patient was considered transfusion dependent.
| participants | Azacitidine | Conventional Care |
|---|---|---|
| Baseline Independent; On-Treatment Independent | 126 | 102 |
| Baseline Independent; On-Treatment Dependent | 15 | 50 |
Investigator determined responses followed IWG criteria for * complete remission(CR): repeat bone marrow show \<5% myeloblasts, and peripheral blood evaluations lasting \>=2 months of hemoglobin(\>110 g/L), neutrophils(\>=1.5x10\^9/L), platelets(\>=100x10\^9/L), blasts (0%) and no dysplasia * partial remission(PR) is the same as CR for peripheral blood: bone marrow shows blasts decrease by \>=50% or a less advanced FAB classification from pretreatment * stable disease(SD) is a failure to achieve at least a partial remission, but with no evidence of progression for at least 2 months.
| participants | Azacitidine | Conventional Care |
|---|---|---|
| Overall (Complete + Partial Remission) | 51 | 21 |
| Complete Remission | 30 | 14 |
| Partial Remission | 21 | 7 |
| Stable Disease | 75 | 65 |
IWG 2000 Criteria: Pretreatment=hemoglobin \<100g/L or RBC transfusion-dependent, platelet count \<100x10\^9/L or platelet transfusion dependent, absolute neutrophil count \<1.5x10\^9/L. Erythroid response: Major-\>20g/L increase or transfusion independent. Minor- 10-20g/L increase or \>=50% decrease in transfusion requirements. Platelet response: Major-absolute increase of \>=30x10\^9/L or platelet transfusion independence. Minor-\>=50% increase. Neutrophil response: Major-\>=100% increase or an absolute increase of \>0.5x10\^9/L. Minor-\>=100% increase and absolute increase of \<0.5x10\^9/L.
| participants | Azacitidine | Conventional Care |
|---|---|---|
| Any Improvement n=177, 178 | 87 | 51 |
| Erythroid Response - Major n=157, 160 | 62 | 17 |
| Erythroid Response - Minor n=157, 160 | 2 | 1 |
| Platelet Response - Major n=141, 129 | 46 | 18 |
| Platelet Response - Minor n=138, 127 | 6 | 4 |
| Neutrophil Response - Major n=131, 111 | 25 | 20 |
| Neutrophil Response - Minor n=131, 111 | 5 | 9 |
The time to disease progression, relapse after complete or partial remission (CR, PR), or death from any cause was defined as the time from the date of randomization until the first date of documented disease progression, relapse after CR or PR, or death from any cause.
| months | Azacitidine | Conventional Care |
|---|---|---|
| Time to Disease Progression, Relapse After Complete or Partial Remission, or Death From Any Cause | 14.13 (9.5 to 27.6) | 8.82 (6.4 to 12.4) |
The duration of improvement was defined as the time from the date of hematologic improvement until the date of first documented progression or relapse after hematologic improvement or death from any cause.
| months | Azacitidine | Conventional Care |
|---|---|---|
| Duration of Any Hematologic Improvement | 13.57 (10.1 to 16.3) | 5.18 (4.1 to 9.7) |
The on-treatment adverse event rate of infection requiring IV antibiotics, antifungals, or antivirals per patient-years. The on-treatment period was considered the period from the date of randomization to the last treatment study visit.
| infections per treatment year | Azacitidine | Conventional Care |
|---|---|---|
| Number of Infections Per Treatment Year Requiring Intravenous Antibiotics, Antifungals or Antivirals | 0.16 | 0.24 |
Patient counts for a variety of subsets of adverse experiences for the core study period (day 1 to 42 months). The individual options for Conventional Care Regimens (Best Supportive Care Only, Low-Dose Cytarabine, and Standard Chemotherapy) are presented as separate treatments.
| participants | Azacitidine | Best Supportive Care Only | Low-dose Cytarabine | Standard Chemotherapy |
|---|---|---|---|---|
| Patients with >=1 treatment emergent AE (TEAE) | 175 | 97 | 44 | 19 |
| Patients with >=1 treatment related TEAE | 169 | 1 | 34 | 19 |
| Patients with >=1 serious TEAE | 114 | 71 | 27 | 14 |
| Patients with >=1 serious treatment related TEAE | 43 | 0 | 13 | 13 |
| Patients w TEAE leading to discontinued treatment | 22 | 4 | 6 | 2 |
| Patients w TEAE leading to dose reduction | 20 | 0 | 2 | 0 |
| Patients w TEAE leading to dose interruption | 82 | 0 | 12 | 0 |
A sensitivity analysis of time to transformation to AML during the entire study was performed based on the last bone marrow assessment. Patients were censored based on the last bone marrow assessment.
| months | Azacitidine | Conventional Care |
|---|---|---|
| Kaplan-Meier Estimates for Median Time to Transformation to Acute Myeloid Leukemia (AML) Based on the Last Bone Marrow Assessment | 17.80 (13.6 to 23.6) | 11.48 (8.3 to 14.5) |
Count of participants who died during the study
| participants | Azacitidine | Conventional Care |
|---|---|---|
| Number of Participants Who Died | 82 | 113 |
Collected over Treatment-emergent AEs for the 'core study' from Day 1 to 42 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Azacitidine | — | 114/175 (65.1%) | 175/175 (100%) |
| Best Supportive Care Only | — | 71/102 (69.6%) | 86/102 (84.3%) |
| Low-dose Cytarabine | — | 27/44 (61.4%) | 44/44 (100%) |
| Standard Chemotherapy | — | 14/19 (73.7%) | 19/19 (100%) |
| Event | Azacitidine | Best Supportive Care Only | Low-dose Cytarabine | Standard Chemotherapy |
|---|---|---|---|---|
| Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 30/175 | 35/102 | 6/44 | 1/19 |
| Febrile neutropeniaBlood and lymphatic system disorders | 19/175 | 3/102 | 1/44 | 5/19 |
| PneumoniaInfections and infestations | 20/175 | 12/102 | 2/44 | 3/19 |
| PyrexiaGeneral disorders | 10/175 | 3/102 | 5/44 | 0/19 |
| Neutropenic colitisGastrointestinal disorders | 0/175 | 0/102 | 0/44 | 2/19 |
| BacteraemiaInfections and infestations | 2/175 | 0/102 | 0/44 | 2/19 |
| Neutropenic sepsisInfections and infestations | 4/175 | 1/102 | 1/44 | 2/19 |
| Pneumonia fungalInfections and infestations | 1/175 | 0/102 | 0/44 | 2/19 |
| AnaemiaBlood and lymphatic system disorders | 12/175 | 3/102 | 2/44 | 0/19 |
| Bone marrow failureBlood and lymphatic system disorders | 2/175 | 0/102 | 0/44 | 1/19 |
| Event | Azacitidine | Best Supportive Care Only | Low-dose Cytarabine | Standard Chemotherapy |
|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 118/175 | 34/102 | 21/44 | 13/19 |
| NeutropeniaBlood and lymphatic system disorders | 114/175 | 29/102 | 15/44 | 10/19 |
| DiarrhoeaGastrointestinal disorders | 38/175 | 18/102 | 10/44 | 12/19 |
| AnaemiaBlood and lymphatic system disorders | 84/175 | 42/102 | 19/44 | 11/19 |
| PyrexiaGeneral disorders | 46/175 | 16/102 | 17/44 | 11/19 |
| ConstipationGastrointestinal disorders | 88/175 | 8/102 | 11/44 | 8/19 |
| NauseaGastrointestinal disorders | 84/175 | 12/102 | 16/44 | 9/19 |
| Injection site erythemaGeneral disorders | 75/175 | 0/102 | 0/44 | 0/19 |
| HypokalaemiaMetabolism and nutrition disorders | 11/175 | 2/102 | 1/44 | 8/19 |
| LeukopeniaBlood and lymphatic system disorders | 31/175 | 2/102 | 3/44 | 6/19 |
| Age, Continuous(years) | Azacitidine | Conventional Care | Total |
|---|---|---|---|
| Mean | 68.0 ± 7.57 | 69.2 ± 7.87 | 68.6 ± 7.73 |
| Sex: Female, Male(Participants) | Azacitidine | Conventional Care | Total |
|---|---|---|---|
| Female | 47 | 60 | 107 |
| Male | 132 | 119 | 251 |
| Race/Ethnicity, Customized(participants) | Azacitidine | Conventional Care | Total |
|---|---|---|---|
| Caucasian | 177 | 175 | 352 |
| Black or African American | 0 | 0 | 0 |
| Asian/Oriental | 2 | 3 | 5 |
| Hispanic | 0 | 1 | 1 |
| Other | 0 | 0 | 0 |
| French-American-British (FAB) Classification(participants) | Azacitidine | Conventional Care | Total |
|---|---|---|---|
| Refractory anemia with excess blasts (RAEB) | 104 | 103 | 207 |
| RAEB in transformation | 61 | 62 | 123 |
| Modified chronic myelomonocytic leukemia | 6 | 5 | 11 |
| Acute myeloid leukemia | 1 | 1 | 2 |
| Myeloproliferative disease | 4 | 2 | 6 |
| Indeterminate | 3 | 6 | 9 |
| International Prognostic Scoring System (IPSS)(participants) | Azacitidine | Conventional Care | Total |
|---|---|---|---|
| Intermediate risk level 1 (0.5-1.0) | 5 | 13 | 18 |
| Intermediate risk level 2 (1.5-2.0) | 76 | 70 | 146 |
| High risk (2.5-3.5) | 82 | 85 | 167 |
| Not applicable | 5 | 3 | 8 |
| Indeterminate | 11 | 8 | 19 |
| World Health Organization (WHO) Classification(participants) | Azacitidine | Conventional Care | Total |
|---|---|---|---|
| Refractory anemia with excess blasts - 1 | 14 | 17 | 31 |
| Refractory anemia with excess blasts - 2 | 98 | 95 | 193 |
| Chronic myelomonocytic leukemia - 1 (CMMoL-1) | 1 | 0 | 1 |
| Chronic myelomonocytic leukemia - 2 (CMMoL-2) | 10 | 5 | 15 |
| Acute myeloid leukemia | 55 | 58 | 113 |
| Indeterminate | 1 | 4 | 5 |
| Body Surface Area(meters squared) | Azacitidine | Conventional Care | Total |
|---|---|---|---|
| Mean | 1.9 ± 0.19 | 1.8 ± 0.19 | 1.9 ± 0.19 |
| Weight(kilograms) | Azacitidine | Conventional Care | Total |
|---|---|---|---|
| Mean | 76.5 ± 14.08 | 74.6 ± 13.58 | 75.6 ± 13.85 |
Showing the first 100 of 108 sites across 15 countries. Choose a country and city above to see the rest.
Ran from Nov 2003 to primary completion in Jul 2007, 44 months.
Results were first posted in Jul 2010, 3 years after primary completion.
Of 26 industry-sponsored phase 3 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 52. This study's 44 months is close to that.
Counting every sponsor, half of 45 studies reached it within 50 months; a quarter within 38 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Azacitidine